Evaluation of the Efficacy and Safety of Endobronchial Ultrasound-Guided Biopsy Using a Cryoprobe

未提供0 个研究点目标入组 85 人开始时间: 待定最近更新: 2025年5月8日

适应症

试验速览

暂无简介。

•Patients suspected of having primary lung cancer based on chest CT or those already diagnosed with primary lung cancer.
•Patients with apparent suspected lymph node metastasis of lung cancer, presenting with mediastinal or hilar lymphadenopathy that meets at least one of the following criteria (Short-axis diameter of >10 mm on chest CT, FDG accumulation with SUV-max >2.5 on PET-CT, These patients require a tissue biopsy via EBUS-TBNA). (Patients requiring differentiation of lymph node metastasis presence or absence are excluded.)
•Patients aged 18 years or older at the time of consent.
•Patients with an ECOG performance status (PS) of 0, 1, or
•Patients without severe dysfunction of major organs (bone marrow, heart, lungs, liver, kidneys, etc.), meeting the following criteria:
•White blood cell count >3,000 /mm3
•Neutrophil count > 1,500 /mm3
•Hemoglobin > 9.0 g/dL
•Platelet count > 100,000 /mm3
•PaO2 > 60 torr or SpO2 > 90%
•Patients with preserved coagulation function sufficient to tolerate bronchoscopy.
•Patients who have received a thorough explanation of the study and have provided written informed consent.

•Patients requiring EBUS-TBNA for multiple lymph nodes.
•Patients with hypersensitivity to lidocaine, midazolam, flumazenil, or pethidine hydrochloride, or those with severe hypersensitivity to other drugs.
•Patients receiving antiplatelet or anticoagulant therapy. (Patients may be included if an appropriate withdrawal period is observed.)
•Patients requiring EBUS-TBNA for lymph nodes with apparent invasion into the hilar vessels, heart, or major blood vessels on imaging.
•Patients with severe comorbidities (such as heart disease, interstitial pneumonia, or uncontrolled hypertension).
•Patients with clinically significant infections.
•Pregnant, lactating, or potentially pregnant patients.
•Patients deemed unsuitable for safe participation in this study by the attending physician.

The proportion of tissue samples containing malignant tumor cells.

发起方

未提供